Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Astrazeneca Plc ADR (NQ: AZN )

65.63 +1.37 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
Eli Lilly's Stock Surge Driven by GLP-1 Demand
Shares of Eli Lilly stock are about to hit a new all-time high, sponsored by the pending approval of new weight loss drugs 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a... 
Via Benzinga
Exposures COVID-19
Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years
Via Benzinga
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial
AstraZeneca announced that the CAPItello-290 Phase 3 trial for Truqap (capivasertib) combined with paclitaxel in advanced or metastatic triple-negative breast cancer did not meet primary endpoints for... 
Via Benzinga
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for... 
Via Benzinga
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
From AstraZeneca
Via Business Wire
FDA Approves AstraZeneca Treatment For Advanced Endometrial Cancer
AstraZeneca's breakthrough drug, Imfinzi, combined with chemotherapy, has been officially approved by the FDA to treat advanced forms of endometrial cancer with mismatch repair deficiency. This... 
Via Benzinga
Exposures Product Safety
3 Best Stocks to Buy From the Fantastic 5
Although the best Fantastic 5 stocks offer much relevance and plenty of upside potential, they’re still underappreciated. 
Via InvestorPlace
AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer
AstraZeneca shares data from the ECHO Phase 3 trial on Calquence plus bendamustine and rituximab in untreated mantle cell lymphoma patients over 65. 
Via Benzinga
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
From AstraZeneca
Via Business Wire
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
The companies are closing in on the finish line for two new COPD treatments. 
Via Investor's Business Daily
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
From AstraZeneca
Via Business Wire
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Enthusiasm is growing for a looming approval in COPD treatment. 
Via Investor's Business Daily
3 Crazy Good Stocks to Buy With $500 Right Now
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth. 
Via InvestorPlace
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services. 
Via Talk Markets
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks
Five mega companies may offer higher earnings and return potential with lower risk. 
Via Investor's Business Daily
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
Via Talk Markets
The No-Brainer Buys: 3 Stocks That Are Absolute Must-Owns Right Now
Discover three of the best must-own stocks, showcasing resilient performance, strategic growth initiatives and consistent dividend payouts. 
Via InvestorPlace
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
These are the overvalued stocks to sell. They represent quality companies that are worth buying after a 20% to 30% downside 
Via InvestorPlace
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
There's probably a big enough pie here for everyone to get a slice. 
Via The Motley Fool
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
From AstraZeneca
Via Business Wire
Stocks Seeing Relentless Buying Pressure; Bonds Are Not
Relentless buying pressure, to the degree that we saw in Q4 last year, is evidence of strong underlying demand for stocks. Meanwhile, after a 40-year drawdown, the 50-week rate of change for US 30-year... 
Via Talk Markets
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
From AstraZeneca
Via Business Wire
3 No-Brainer Stocks to Buy in June
Now is the time to invest in these great stocks. 
Via The Motley Fool
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
AstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company should be able to repeat this feat over the next 10 years. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.